|Title||Proteomics in uveal melanoma.|
|Publication Type||Journal Article|
|Year of Publication||2022|
|Authors||Heiferman, Michael J., Mahajan Vinit B., and Mruthyunjaya Prithvi|
|Journal||Curr Opin Ophthalmol|
|Date Published||2022 Jan 31|
PURPOSE OF REVIEW: This article reviews the latest proteomic research on uveal melanoma.
RECENT FINDINGS: Proteomic analysis of uveal melanoma cell lines and tissue specimens has improved our understanding of the pathophysiology of uveal melanoma and helped identify potential prognostic biomarkers. Circulating proteins in patient serum may aid in the surveillance of metastatic disease. The proteomes of aqueous and vitreous biopsy specimens may provide safer biomarkers for metastatic risk and candidate therapeutic targets in uveal melanoma. Proteomic analysis has the potential to benefit patient outcomes by improving diagnosis, prognostication, surveillance, and treatment of uveal melanoma.
SUMMARY: These recent findings demonstrate that proteomic analysis is an important area of research to better understand the pathophysiology of uveal melanoma and improve the personalized management of our patients.
|Alternate Journal||Curr Opin Ophthalmol|